Go Pro
→ Small Colorado Company (Backed by Sam Altman) Could Save U.S. Power Grid (From Altimetry) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Achaogen, Inc. stock logo
AKAOQ
Achaogen
$0.03
+0.8%		$0.02
$0.00
▼
$0.05
$1.21M-0.81186,196 shs68,500 shs
ASLAN Pharmaceuticals Limited stock logo
ASLN
ASLAN Pharmaceuticals
$0.60
$0.60
$0.48
▼
$25.44
$1.23M1.4122,322 shsN/A
GelStat Corp. stock logo
GSAC
GelStat
$0.00
$0.00
$0.00
▼
$0.00
$1.12M1.6864,640 shsN/A
Lyra Therapeutics, Inc. stock logo
LYRA
Lyra Therapeutics
$0.20
$0.33
$0.00
▼
$8.75
$350K0.58649 shsN/A
The 7 Hottest IPO Stories of 2026 Cover
The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Achaogen, Inc. stock logo
AKAOQ
Achaogen
0.00%0.00%0.00%0.00%0.00%
ASLAN Pharmaceuticals Limited stock logo
ASLN
ASLAN Pharmaceuticals
0.00%0.00%0.00%0.00%0.00%
GelStat Corp. stock logo
GSAC
GelStat
0.00%+50.00%0.00%0.00%-25.00%
Lyra Therapeutics, Inc. stock logo
LYRA
Lyra Therapeutics
0.00%0.00%-20.00%-63.64%-96.88%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Achaogen, Inc. stock logo
AKAOQ
Achaogen
$0.03
+0.8%		$0.02
$0.00
▼
$0.05
$1.21M-0.81186,196 shs68,500 shs
ASLAN Pharmaceuticals Limited stock logo
ASLN
ASLAN Pharmaceuticals
$0.60
$0.60
$0.48
▼
$25.44
$1.23M1.4122,322 shsN/A
GelStat Corp. stock logo
GSAC
GelStat
$0.00
$0.00
$0.00
▼
$0.00
$1.12M1.6864,640 shsN/A
Lyra Therapeutics, Inc. stock logo
LYRA
Lyra Therapeutics
$0.20
$0.33
$0.00
▼
$8.75
$350K0.58649 shsN/A
The 7 Hottest IPO Stories of 2026 Cover
The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Achaogen, Inc. stock logo
AKAOQ
Achaogen
0.00%0.00%0.00%0.00%0.00%
ASLAN Pharmaceuticals Limited stock logo
ASLN
ASLAN Pharmaceuticals
0.00%0.00%0.00%0.00%0.00%
GelStat Corp. stock logo
GSAC
GelStat
0.00%+50.00%0.00%0.00%-25.00%
Lyra Therapeutics, Inc. stock logo
LYRA
Lyra Therapeutics
0.00%0.00%-20.00%-63.64%-96.88%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Achaogen, Inc. stock logo
AKAOQ
Achaogen
0.00
N/AN/AN/A
ASLAN Pharmaceuticals Limited stock logo
ASLN
ASLAN Pharmaceuticals
0.00
N/AN/AN/A
GelStat Corp. stock logo
GSAC
GelStat
0.00
N/AN/AN/A
Lyra Therapeutics, Inc. stock logo
LYRA
Lyra Therapeutics
1.00
SellN/AN/A

Current Analyst Ratings Breakdown

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Achaogen, Inc. stock logo
AKAOQ
Achaogen
$8.73M0.14N/AN/AN/A∞
ASLAN Pharmaceuticals Limited stock logo
ASLN
ASLAN Pharmaceuticals
$12M0.10N/AN/A($6.50) per share-0.09
GelStat Corp. stock logo
GSAC
GelStat
N/AN/AN/AN/AN/AN/A
Lyra Therapeutics, Inc. stock logo
LYRA
Lyra Therapeutics
$400K0.89N/AN/A($6.04) per share-0.03
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Achaogen, Inc. stock logo
AKAOQ
Achaogen
-$186.51MN/AN/AN/AN/AN/AN/AN/AN/A
ASLAN Pharmaceuticals Limited stock logo
ASLN
ASLAN Pharmaceuticals
-$44.22M-$21.92N/AN/AN/AN/A-8,454.87%-121.60%N/A
GelStat Corp. stock logo
GSAC
GelStat
N/AN/AN/AN/AN/AN/AN/AN/AN/A
Lyra Therapeutics, Inc. stock logo
LYRA
Lyra Therapeutics
-$28.92M-$19.15N/AN/AN/A-7,266.08%N/A-59.82%11/17/2026 (Estimated)
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Achaogen, Inc. stock logo
AKAOQ
Achaogen
N/AN/AN/AN/AN/A
ASLAN Pharmaceuticals Limited stock logo
ASLN
ASLAN Pharmaceuticals
N/AN/AN/AN/AN/A
GelStat Corp. stock logo
GSAC
GelStat
N/AN/AN/AN/AN/A
Lyra Therapeutics, Inc. stock logo
LYRA
Lyra Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Achaogen, Inc. stock logo
AKAOQ
Achaogen
N/AN/AN/A
ASLAN Pharmaceuticals Limited stock logo
ASLN
ASLAN Pharmaceuticals
N/A
1.05
1.05
GelStat Corp. stock logo
GSAC
GelStat
N/AN/AN/A
Lyra Therapeutics, Inc. stock logo
LYRA
Lyra Therapeutics
N/A
1.71
1.71

Institutional Ownership

CompanyInstitutional Ownership
Achaogen, Inc. stock logo
AKAOQ
Achaogen
N/A
ASLAN Pharmaceuticals Limited stock logo
ASLN
ASLAN Pharmaceuticals
58.82%
GelStat Corp. stock logo
GSAC
GelStat
N/A
Lyra Therapeutics, Inc. stock logo
LYRA
Lyra Therapeutics
95.62%

Insider Ownership

CompanyInsider Ownership
Achaogen, Inc. stock logo
AKAOQ
Achaogen
7.80%
ASLAN Pharmaceuticals Limited stock logo
ASLN
ASLAN Pharmaceuticals
4.69%
GelStat Corp. stock logo
GSAC
GelStat
20.50%
Lyra Therapeutics, Inc. stock logo
LYRA
Lyra Therapeutics
3.25%
CompanyEmployeesShares OutstandingFree FloatOptionable
Achaogen, Inc. stock logo
AKAOQ
Achaogen
4248.21 millionN/ANot Optionable
ASLAN Pharmaceuticals Limited stock logo
ASLN
ASLAN Pharmaceuticals
302.04 million1.95 millionNo Data
GelStat Corp. stock logo
GSAC
GelStat
23.74 billion2.97 billionNot Optionable
Lyra Therapeutics, Inc. stock logo
LYRA
Lyra Therapeutics
501.77 million1.72 millionNo Data

Recent News About These Companies

Lyra Therapeutics Inc.
August 29, 2026  |  marketwatch.comhttps://www.marketwatch.com/investing/stock/lyra/financials/cash-flow
Lyra Therapeutics Ends Major Office Sublease Agreement
April 17, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/lyra-therapeutics-ends-major-office-sublease-agreement?utm_source=marketbeat.com&utm_medium=referral
Lyra Therapeutics, Inc. Announces Intention to Voluntarily File Form 25 for Delisting from Nasdaq and Subsequent Deregistration with the SEC
April 17, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/04/17/3276116/0/en/lyra-therapeutics-inc-announces-intention-to-voluntarily-file-form-25-for-delisting-from-nasdaq-and-subsequent-deregistration-with-the-sec.html
After layoffs, Lyra Therapeutics exits Watertown and Waltham leases
April 14, 2026  |  bizjournals.comhttps://www.bizjournals.com/boston/news/2026/04/13/lyra-terminates-leases.html
Lyra Therapeutics Walks Away From Watertown, Waltham Lab Space
April 14, 2026  |  hoodline.comH
Treating allergic fungal rhinosinusitis in children
April 8, 2026  |  msn.comhttps://www.msn.com/en-us/health/other/treating-allergic-fungal-rhinosinusitis-in-children/ar-AA20r233
Lyra Therapeutics Withdraws Nasdaq Appeal, Faces Imminent Delisting
March 16, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/lyra-therapeutics-withdraws-nasdaq-appeal-faces-imminent-delisting?utm_source=marketbeat.com&utm_medium=referral
Lyra Therapeutics (LYRA) price target decreased by 30.43% to 16.32
February 4, 2026  |  msn.comhttps://www.msn.com/en-us/money/topstocks/lyra-therapeutics-lyra-price-target-decreased-by-3043-to-1632/ar-AA1VETSX
Lyra Therapeutics suspends further development of LYR-210
January 13, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/news/lyra-therapeutics-suspends-further-development-122631308.html
Lyra ditches sole rhinosinusitis asset, lays off all employees
January 13, 2026  |  fiercebiotech.comF
Watertown biotech suspends drug development and eliminates workforce as cash dwindles
January 12, 2026  |  bizjournals.comhttps://www.bizjournals.com/boston/news/2026/01/12/lyra-layoffs-halt-development.html
Lyra Therapeutics Suspends Development of Lead Product Candidate
January 12, 2026  |  marketwatch.comhttps://www.marketwatch.com/story/lyra-therapeutics-suspends-development-of-lead-product-candidate-c11f109d
Lyra Therapeutics Provides Corporate Update
January 12, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/01/12/3216724/0/en/lyra-therapeutics-provides-corporate-update.html
William Blair Reaffirms Their Hold Rating on Lyra Therapeutics (LYRA)
November 15, 2025  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/LYRA/pressreleases/35290143/william-blair-reaffirms-their-hold-rating-on-lyra-therapeutics-lyra/
Insider Selling: Lyra Therapeutics (NASDAQ:LYRA) Major Shareholder Sells 5,320 Shares of Stock
November 14, 2025  |  insidertrades.comhttps://www.insidertrades.com/alerts/nasdaq-lyra-insider-buying-and-selling-2025-11-14/
21 Companies Miss Massachusetts Hiring Targets, Affecting Hundreds of Jobs
November 13, 2025  |  biospace.comB
Lyra Therapeutics Faces Financial Challenges Amid Clinical Setbacks
November 13, 2025  |  msn.comhttps://www.msn.com/en-us/science/general/lyra-therapeutics-faces-financial-challenges-amid-clinical-setbacks/ar-AA1QlGXU
Lyra Therapeutics, Inc. (LYRA) Reports Q3 Loss, Lags Revenue Estimates
November 12, 2025  |  zacks.comhttps://www.zacks.com/stock/news/2790202/lyra-therapeutics-inc-lyra-reports-q3-loss-lags-revenue-estimates?cid=cs-stocknewsapi-ft-tale_of_the_tape|yseop_template_4-2790202
Lyra Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
November 12, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/11/12/3186723/0/en/lyra-therapeutics-reports-third-quarter-2025-financial-results-and-provides-corporate-update.html
Perceptive Advisors Llc Sells 18,502 Shares of Lyra Therapeutics (NASDAQ:LYRA) Stock
November 11, 2025  |  insidertrades.comhttps://www.insidertrades.com/alerts/nasdaq-lyra-insider-buying-and-selling-2025-11-11/

New MarketBeat Followers Over Time

Achaogen stock logo

Achaogen OTCMKTS:AKAOQ

$0.03 +0.00 (+0.81%)
As of 06/18/2021

Achaogen, Inc., a biopharmaceutical company, focuses on the development and commercialization of antibacterial agents for multi-drug resistant (MDR) gram-negative infections in the United States. The company is principally developing plazomicin for the treatment of serious bacterial infections due to MDR enterobacteriaceae comprising carbapenem-resistant enterobacteriaceae. It is also involved in the development of antibacterial candidate C-Scape, an orally-administered combination of clavulanate and ceftibuten, which targets serious bacterial infections due to expanded spectrum beta-lactamases producing enterobacteriaceae. The company has license and collaboration agreements with Thermo Fisher Scientific, Inc. to develop and commercialize an assay to support plazomicin; Crystal Biosciences, Inc. to discover monoclonal antibodies against multiple targets; Ionis Pharmaceuticals, Inc. for certain patents relating to aminoglycoside antibacterial compounds and related know-how to develop and commercialize certain novel aminoglycoside antibacterial compounds; and Hovione Limited manufacture the active pharmaceutical ingredient for plazomicin. The company was incorporated in 2002 and is based in South San Francisco, California. On April 15, 2019, Achaogen, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware. The plan was later approved as Chapter 11 liquidation on May 29, 2020.

ASLAN Pharmaceuticals stock logo

ASLAN Pharmaceuticals NASDAQ:ASLN

$0.60 0.00 (0.00%)
As of 09/10/2026

ASLAN Pharmaceuticals Limited, a clinical-stage immunology focused biopharmaceutical company, engages in developing various treatments to transform the lives of patients. The company's clinical portfolio comprises eblasakimab (ASLAN004), a monoclonal antibody that targets the IL-13 receptor a1 subunit which is under Phase 2 developed for the treatment of atopic dermatitis and other immunology indications; and farudodstat (ASLAN003), an orally active, potent inhibitor of human dihydroorotate dehydrogenase currently under Phase 2 clinical trials for the treatment of autoimmune diseases. It has research collaboration agreement with Zenyaku Kogyo Co., Ltd. for the development and commercialization of eblasakimab in atopic dermatitis and all other indications in Japan. The company was founded in 2010 and is headquartered in Singapore.

GelStat stock logo

GelStat OTCMKTS:GSAC

$0.0003 0.00 (0.00%)
As of 09/9/2026

GelStat Corporation, a consumer health care company, engages in the research, development, and marketing of over-the-counter and other non-prescription consumer health care products. Its products include GelStat Migraine, a patented solution used for pain relief from migraine headaches; Chews 2 Lose, an appetite suppressant gum for diet aide; All Natural Speed, an energy supplement product; and GelStat Sleep, a product for relief from sleep disorders and its associated symptoms. The company sells its products to retailers, wholesalers, specialty distributors, and catalog merchandisers both directly and through external sales brokers. GelStat Corporation was founded in 2002 and is headquartered in Palm City, Florida.

Lyra Therapeutics stock logo

Lyra Therapeutics OTCMKTS:LYRA

$0.20 0.00 (0.00%)
As of 09/10/2026

Lyra Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. It's XTreo technology platform is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. The company's product candidates include LYR-210, an anti-inflammatory implantable drug matrix for the treatment of chronic rhinosinusitis (CRS), which is in Phase III clinical trial; and LYR-220 for CRS patients with and without nasal polyps. It has a collaboration agreement with LianBio Inflammatory Limited to develop and commercialize LYR-210 in mainland China, Hong Kong, Taiwan, Macau, South Korea, Singapore, and Thailand. The company was formerly known as 480 Biomedical, Inc. and changed its name to Lyra Therapeutics, Inc. in July 2018. Lyra Therapeutics, Inc. was incorporated in 2005 and is headquartered in Watertown, Massachusetts.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas